HOME >> MEDICINE >> NEWS
MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology

St. Louis, MO, May 31, 2001--MetaPhore Pharmaceuticals, Inc. today announced that it has received FDA approval of its Investigational New Drug (IND) application to conduct clinical trials in the U.S. to evaluate M40403, one of its enzyme mimetic compounds.

MetaPhore has initiated a Phase I study to test the safety and tolerability and to determine the pharmacokinetics of the compound in normal, healthy human subjects, as a precursor to Phase II trials in which M40403 will be tested as a co-therapy with interleukin-2 (IL-2) for advanced skin and end-stage kidney cancers. This study is the first human clinical trial for MetaPhore and the companys proprietary family of enzyme mimetic compounds that effectively mimic the action of one of the bodys primary free-radical fighting mechanisms, the natural enzyme superoxide dismutase (SOD).

In addition to cancer, MetaPhore is developing these compounds as drug candidates for pain and other diseases and conditions that have been associated with free-radical damage to tissues and cells.

The opening of this IND marks a major step for MetaPhore and our SOD enzyme mimetic program. For many years, we have understood the free-radical fighting power of the bodys natural SOD enzymes, but only recently have we been able to reproduce that benefit in a stable and selective drug form, said Denis Forster, Chief Operating Officer of MetaPhore. These novel therapeutics have tremendous potential, based on the growing body of research linking free-radical mediated damage with a wide range of acute and chronic disease states.

Preclinical studies in animals, including several recently presented at the American Association for Cancer Research at the end of March, have shown that M40403 significantly improves the effectiveness of IL-2, an approved treatment for inoperable metastatic melanoma and metastatic renal-cell carcinoma. Approximately 80,000 cases of melanoma and renal-cell carcinoma are diagnosed in th
'"/>

Contact: Punnie Donohue
pdonohue@kupperparker.com
314-290-2014
Kupper Parker Communications
30-May-2001


Page: 1 2 3

Related medicine news :

1. NIH awards grant to MetaPhore Pharmaceuticals to study novel pain treatments
2. Eyetech Pharmaceuticals, Inc. announces macugen data on treating macular degeneration
3. Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy
4. Aventis Pharmaceuticals Allegra (Fexofenadine Hcl) 30-Mg tablets now available to treat seasonal allergies, chronic hives in children 6 to 11 years
5. Pharmaceuticals and personal care products
6. Nortran Pharmaceuticals Inc. and Hoechst Marion Roussel announce collaborativeagreement
7. Signal Pharmaceuticals Announces Positive Results In Preclinical Study Of Novel Drug Leads For Treatment Of Osteoporosis
8. Beyond Pharmaceuticals: Business And Academic Leaders Forecast The Future Of "Combinatorial Chemistry"
9. ONYX Pharmaceuticals Reports Phase II Clinical Trial Results At ASCO Meeting
10. NIAID initiates trial of experimental avian flu vaccine
11. American Academy of Neurology initiates health literacy training for neurologists

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/30/2021)... , ... March 29, 2021 , ... ... the 21st Century , A Virtual Workshop Presented by WCG FDAnews and Cerulean ... 4:30 pm EDT, https://wcg.swoogo.com/modern-sop-and-quality-systems , Are one’s SOPs written for the ...
(Date:3/30/2021)... ... March 29, 2021 , ... According to data released ... reproductive age (13-44) in need of publicly funded contraception live in counties impacted by ... Colorado’s 64 counties have lost some of their Title X resources. , The ...
(Date:3/30/2021)... ... March 29, 2021 , ... Health Literacy Innovations (HLI), a ... confusion due to low health literacy today announces a new partnership with the ... work with ACAP’s member Safety Net Health Plans, those that provide comprehensive health ...
(Date:3/30/2021)... ... ... Dr. Colin Campbell is proud to announce the 1 year anniversary in their new state ... internal medicine and is a primary care specialist who has been practicing for 23 years. ... keep South Jersey healthy one patient at a time. , “Over the past year, Dr. ...
(Date:3/30/2021)... ... March 30, 2021 , ... The COVID-19 ... and survivors; their families; and their caregivers. Crossroads4Hope is addressing the needs of ... emotional support system, MyGo2Support, which meets needs of people impacted by cancer, no ...
Breaking Medicine News(10 mins):
(Date:3/30/2021)... ... March 29, 2021 , ... The University of Texas Health Science Center ... San Antonio Multispecialty and Research Hospital, a destination center for research and treatment of ... In a nod to the COVID-19 pandemic, the ceremony was held virtually. , William ...
(Date:3/30/2021)... ... March 29, 2021 , ... Iora Health ... primary care, has partnered with Devoted Health , one of the fastest-growing ... across Maricopa County and provides seniors with the highest-quality care and experience possible, ...
(Date:3/30/2021)... CITY (PRWEB) , ... March 29, 2021 , ... ... has joined the Vaccine Credential Initiative (VCI), a group bringing together leading health ... record of vaccination status, based on open, interoperable standards. By joining the VCI ...
Breaking Medicine Technology:
Cached News: